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ABSTRACT 
The clinical use of aminoglycoside (AG) antibiotics is limited by their renal toxicity, 
which is caused by drug accumulation in proximal tubule (PT) cells. Clinical studies 
reported that renal clearance of AG is enhanced in cystic fibrosis (CF) patients, which 
might reflect the role of CFTR in PT cell endocytosis. In order to assess the role of 
chloride transporters on the renal handling of AG, we investigated gentamicin uptake and 
clearance in mice lacking functional CFTR (Cftr∆F/∆F) or knock-out for the Cl-/H+ 
exchanger ClC-5 (Clcn5Y/-). The latter represent a paradigm of PT dysfunction and 
defective receptor-mediated endocytosis. As compared with controls, Cftr∆F/∆F and 
Clcn5Y/- mice showed a 30% to 60% increase in renal gentamicin clearance, respectively. 
The enhanced clearance was associated with a lower renal accumulation of gentamicin. 
Studies on primary cultures of Cftr∆F/∆F and Clcn5Y/- mouse PT cells confirmed the 
reduction in gentamicin uptake, although colocalization with endosomes and lysosomes 
was maintained. Quantification of endocytosis in PT cells revealed that gentamicin, 
similar to albumin, preferentially binds to megalin. The functional loss of ClC-5 or CFTR 
was reflected by a decrease of the endocytic uptake of gentamicin, with a more 
pronounced effect in cells lacking ClC-5. These results support the concept that CFTR, as 
well as ClC-5, plays a relevant role in PT cell endocytosis and also demonstrate that their 
functional loss is associated with impaired uptake of AG in PT cells, causing an enhanced 
renal clearance of the drug. 
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INTRODUCTION 
Aminoglycosides (AG) are among the most commonly used antibiotics 
worldwide. Their activity against a wide range of Gram-negative bacteria combined with 
a low rate of reversible resistance make AG the drug of choice to treat life-threatening 
infections. However, nephrotoxicity of AG, which is observed in up to 25% of treated 
patients, represent a serious adverse event and is a dose limiting factor for their 
therapeutic use [1,17]. AG are commonly used to treat exacerbations of pulmonary 
infections (particularly with Pseudomonas aeruginosa) in patients with cystic fibrosis 
(CF). Nephrotoxicity of AG is particularly burdensome in such patients, considering the 
tenacity of infections and the necessity for repeated treatment courses [24]. A further 
aspect is that CF patients show enhanced renal clearance for many drugs including AG 
[13,28]. The molecular basis of such enhanced drug clearance in CF – increase in 
filtration, decrease in tubular reabsorption or increase in tubular secretion – is debated 
and is probably drug-specific [25]. 
Aminoglycosides are non-protein-bound drugs characterized by low tissue 
penetrance and free glomerular filtration. Around 80% of the administered dose is 
excreted into the urine within 24h. However, up to 5% of the dose is reabsorbed in the 
proximal tubule (PT), where the drug accumulates for a long time (half-life >100h), 
leading to renal damage [22,31]. Aminoglycoside-induced kidney failure is typically non-
oliguric, with evidence of PT dysfunction (renal Fanconi syndrome) and occasional 
toxicity in more distal tubular segments, as reflected by NaCl or magnesium wasting. 
However, accumulation within the renal cortex, especially in PT cells, is thought to be 
play a key role in the pathogenesis of AG nephrotoxicity [14].  
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Experiments in rat models have revealed that accumulation of AG in PT cells is 
mediated by the multi-ligand receptor, megalin [16]. Megalin and its co-receptor cubilin 
are abundantly expressed at the apical surface of PT cells, where they mediate the main 
endocytic pathway for clearance of low-molecular-weight (LMW) proteins that are 
ultrafiltered by the glomerulus [4]. Rare human disorders caused by loss-of-function 
mutations in the genes coding for megalin or cubilin, as well as animal models with 
invalidated megalin or cubilin receptors are invariably associated with urinary loss of 
LMW ligands [6]. Apart from these receptors, recent studies have revealed that 
intravesicular chloride transporters may also play an important role in the reabsorption of 
ultrafiltered ligands [12]. In particular, the vesicular Cl-/H+ exchanger, ClC-5, is crucial 
for receptor-mediated endocytosis and megalin/cubilin trafficking in PT cells [5,19,30]. 
Mutations of the CLCN5 gene that encodes ClC-5 cause Dent’s disease (OMIM #30009), 
a rare X-linked renal tubulopathy characterized by a generalized dysfunction of the PT 
associated with LMW proteinuria [8]. More recently, Jouret et al. have demonstrated that 
loss-of-function mutations in in the CF transmembrane conductance regulator (CFTR, 
ABCC7) gene induce a moderate but significant PT alteration of LMW protein handling 
[11]. Indeed, in mouse kidney, CFTR co-distributes with ClC-5 and the vacuolar-ATPase 
in endosomes located in the apical area of PT cells. Furthermore, lack of CFTR in renal 
PT cells induces instability of cubilin at the brush border, leading to its accelerated 
shedding into urine and LMW proteinuria in CF mice and patients [11]. Accordingly, a 
reduced uptake of AG by PT cells could provide a mechanistic explanation for the 
enhanced renal clearance of AG observed in CF. 
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 In order to test this hypothesis and investigate kidney handling of AG, we 
performed in vivo and in vitro studies to characterize gentamicin handling by PT cells. 
We used two clinically relevant animal models, i.e. mice lacking functional CFTR 
(Cftr∆F/∆F) and those knock-out for ClC-5 (Clcn5Y/-), a well-established model for Dent's 
disease and defective PT cell endocytosis.  
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MATERIALS AND METHODS 
Mouse models 
Experiments were conducted on age- and gender-matched Cftr+/+ and mutated Cftr∆F/∆F 
mice (FVB/129 background) [29]; and Clcn5Y/+ and Clcn5Y/- mice (C57BL6 background) 
[30]. All mice had free access to appropriate standard diet (Carfil Quality, Oud-Turnhout, 
Belgium). The tap water of the Cftr mice was enriched with Movicol (55.2 g/L; Norgine, 
Heverlee, Belgium). The experiments were conducted in accordance with the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals and were 
approved by Ethics Committee of the Université catholique de Louvain. 
 
Clearance studies 
Mice were injected with a therapeutic dose (5mg/kg body weight) gentamicin (Schering-
Plough, Brussels, Belgium) [9]. Blood was obtained by retro-orbital puncture after 30 
min, under anesthesia with Anesketin (Eurovet, Brussels, Belgium) and Rompun (Bayer, 
Brussels, Belgium). Subsequently mice were kept in metabolic cages for 24h with ad 
libitum access to food and drinking water. Urine was collected and blood was obtained by 
puncture of the vena cava at the time of killing. Plasma and urine concentrations of 
gentamicin were determined using an AxSYM System (detection limit: 0.2 µg/mL; 
Abbott Laboratories, Abbott Park, IL, USA). The renal gentamicin clearance was 
measured using the formula UxV/P, where U is the urine gentamicin concentration, V the 
total urine volume, and P the plasma gentamycin concentration. Biological parameters in 
plasma and urine were measured with a Synchron CX5 analyzer (Beckman Coulter, 
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Fullerton, CA), whereas Clara Cell protein (CC16) concentration, a 16-kD marker of PT 
dysfunction, was determined in duplicate by latex immunoassay [30].  
A kidney was split in two parts, and half was fixed for 6h at 4°C in 4% 0.1 M phosphate 
buffered (pH 7.4) formaldehyde (Boehringer Ingelheim, Heidelberg, Germany) and the 
other half was flash-frozen and stored at -80°C. The contralateral kidney was 
homogenized in 0.25 M sucrose and 3 mM imidazole Buffer (pH 7.4) that contained 
Complete (Roche), in a Potter-Elvehjem tissue homogenizer (Thomas Scientific, 
Swedsboro, NJ) [11]. The homogenate was centrifuged at 1000 X g for 15 min at 4°C 
and the supernatant were analyzed biochemically for gentamicin concentration using the 
AxSYM System. 
 
Primary cell culture 
Primary mouse proximal tubule cells (mPTC) were cultured under sterile conditions from 
collagenase-digested cortical fragments of kidneys isolated from male Clcn5 and Cftr 
mice as previously described [26,27]. Seven-day-old confluent monolayers, which retain 
their differentiation and endocytic capacity [20] were used for experiments. 
 
Immunostaining 
Kidney samples and mPTC were fixed in 4% formaldehyde before embedding in paraffin 
as described [11]. After incubation with 10% serum, kidney sections or mPTC were 
incubated with primary antibodies diluted in phosphate-buffered saline (PBS) containing 
2% bovine serum albumin (BSA). After washing, sections were incubated with 
biotinylated secondary anti-IgG antibodies (Vector Laboratories, Brussels, Belgium). 
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Sections were viewed under a Leica DMR coupled to a Leica DC300 digital camera 
(Leica, Heerbrug, Switzerland). For immunofluorescence, Alexa-conjugated secondary 
anti-IgG antibodies were used (Invitrogen, Merelbeke, Belgium). Nuclei were stained 
with DraQ5™ (Biostatus, UK). Filters were cut from the holder and mounted in Prolong 
Gold Anti-fade reagent (Invitrogen, Belgium). Sections were analyzed under a Zeiss 
LSM510Meta Confocal microscope (Zeiss, Belgium). 
 
Antibodies 
Immunostaining analyses were performed using well-characterized rabbit monoclonal 
antibody against gentamicin (a gift from K. Fujiwara, Sojo University, Japan) [10]; 
mouse monoclonal antibody against early endosomal antigen-1 (EEA1); and polyclonal 
antibodies against megalin (a gift from P. Verroust, INSERM, Paris, France).  
 
Gentamicin Endocytosis 
Characterization of the gentamicin uptake was performed in fixed and live mPTC. 
Confluent monolayers of mPTC, isolated from Clcn5 and Cftr mice, were exposed to 5 
mg/ml gentamicin for 7 or 45 min at 37°C, fixed in 4% formaldehyde (see above) and 
subsequently stained with anti-EEA1 and anti-gentamicin. For live-cell imaging, 
confluent monolayers of mPTC were simultaneously incubated with 1 mg/ml Alexa 488-
gentamicin and Lysotracker Red (Invitrogen, Merelbeke, Belgium) for 7 min at 37°C and 
washed. Fluorescence was chased up to 45min after exposure of the cells to gentamicin. 
Cells were examined using the Zeiss LSM510Meta confocal microscope. 
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Quantification of endocytosis was performed as previously described [20]. Confluent 
mPTC were incubated with Alexa488-conjugated gentamicin or Alexa488-conjugated 
BSA (both at 0.5 mg/ml) for 15 min at 37°C. After incubation, mPTC were washed 5 
times with cold HBSS (4°C) and lysed. The fluorescence in the lysate was measured in a 
fluorimeter (Perkin Elmer) with excitation at 490±10 nm and emission at 525±10 nm. For 
metabolic inhibition experiments, mPTC were incubated with 10mM sodium azide or 
50mM 2-deoxyglucose (DOG) for 30 min at 37°C before the endocytic assay. For 
competition experiments, mPTC were simultaneously incubated with 50mM unlabelled 
albumin or transferrin. Fluorescence was normalized for the amount of protein in the 
cells, measured using the BCA kit (Pierce, Belgium).  
Data are expressed as mean ± SEM. Significance of differences was assessed by 
unpaired, two-tailed Student's t-test. 
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RESULTS 
Clearance of gentamicin in Cftr and Clcn5 mice 
We first investigated renal function and gentamicin clearance in Cftr∆F/∆F and Clcn5Y/- 
mice in comparison with their corresponding control littermates. Clearance values and 
renal accumulation of gentamicin were obtained in mice injected i.p. with gentamicin and 
kept in metabolic cages for 24h. Renal function as measured by creatinine clearance, 
BUN and plasma creatinine levels, was similar for CFTR and ClC-5 mice as compared 
with their wild-type controls (Table 1). However, Cftr∆F/∆F mice showed a significant 
increase in the urinary albumin excretion as well as LMW proteinuria as evidenced by the 
increased urinary excretion of CC16. The Clcn5Y/- mice also presented with albuminuria 
and LMW proteinuria, in a greater extent than that observed in Cftr∆F/∆F mice. The Clcn5 
knock-out mice also showed polyuria (Table 1).  
Analysis of gentamicin handling (Table 2) showed that Cftr∆F/∆F mice had a 24% increase 
in the gentamicin clearance, as reflected by a lower kidney accumulation of gentamicin. 
The Clcn5Y/- mice showed a higher (66%) increase in gentamicin clearance as compared 
to controls, with very low levels of gentamycin in Clcn5Y/- kidneys. These results show 
that, even in absence of renal failure, the clearance of gentamicin is significantly 
increased in mouse models of CF and Dent's disease in parallel with the degree of PT 
dysfunction in these models. 
 
Immunolocalization of gentamicin and megalin in Cftr and Clcn5 kidneys 
To substantiate the clearance data, we performed immunostaining for gentamicin (Fig. 1, 
panel A) on kidney sections taken from Cftr and Clcn5 mice 24h post-injection. 
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Gentamicin was clearly detectable in PT sections of both Cftr+/+ and Clcn5Y/+ kidneys, 
contrasting with decreased immunoreactivity in Cftr∆F/∆F and Clcn5Y/- kidneys. A 
residual, faint signal for gentamicin could be observed in PT profiles from the Cftr∆F/∆F 
while no residual signal was detected in Clcn5Y/- mice. Since gentamicin preferentially 
binds to megalin, we investigated the immunoreactivity for megalin in kidney sections of 
gentamicin exposed Cftr and Clcn5 mice (Fig. 1, panel B). In comparison with wild-type 
kidneys, only a faint signal for megalin could be observed at the apical region of PT in 
Clcn5Y/- kidneys, whereas megalin expression was almost unchanged in Cftr∆F/∆F kidneys. 
These in vivo data suggest that the enhanced urinary excretion of gentamicin could result 
from a decreased receptor-mediated uptake in PT cells.  
 
Uptake of gentamicin in mPTC from Clcn5 and Cftr mice 
We used a well-characterized mPTC culture system to evaluate the subcellular handling 
of gentamicin and its dependence on CFTR and ClC-5 in PT cells. Primary cultures of 
mPTC obtained from wild-type (Fig. 2, panels A-D), Clcn5Y/- (Fig. 2, panels E-H) and 
Cftr∆F/∆F (Fig. 2, panels I-L) mice were exposed to gentamicin at 37°C for 7 min (early 
endocytosis) and 45 min (late endocytosis and lysosomal processing). In comparison with 
wild-type mPTC (panels A-B), the gentamicin uptake after 7 min was strongly reduced in 
Clcn5Y/- cells (panels E-F), while a milder reduction was observed in Cftr∆F/∆F mPTC 
(panels I-J). At 45 min, numerous large gentamicin-positive vesicles could be observed in 
wild-type mPTC (panels C-D). A smaller number of positive vesicles was detected in 
Clcn5Y/- (panels G-H) and Cftr∆F/∆F (panels K-L) mPTC.  
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We next used mPTC to identify the localization of gentamicin within the endosomal-
lysosomal pathway. Monolayers of mPTC were double stained for gentamicin and anti-
early endosomal antigen-1 (EEA1) after incubation with gentamicin for 7 min (Fig. 3). In 
wild-type mPTC, gentamicin colocalized with EEA1, confirming its presence in the early 
endosomes (Fig. 3, panels A-C). By contrast, almost no gentamicin could be detected in 
Clcn5Y/- mPTC (Fig. 3, panel D), whereas a markedly reduced staining was detected in 
Cftr∆F/∆F mPTC (Fig. 3, panel G). The few vesicles that contained gentamicin stained 
positive for EEA1, indicating the involvement of early endosomes (Fig. 3, panel I). 
A pulse-chase experiment was performed to investigate the progression of gentamicin 
into the lysosomal compartment of mPTC (Fig. 4). Monolayers of wild-type (Fig. 4, 
panels A-C), Clcn5Y/- (Fig. 4, panels D-F) and Cftr∆F/∆F mPTC (Fig. 4, panels G-I) were 
exposed to Alexa 488-gentamicin and Lyso Tracker Red and gentamicin localization was 
analyzed after 45 min. In wild-type mPTC, gentamicin colocalized with LysoTracker Red 
(panel C) confirming intra-lysosomal capture. A reduction of gentamicin uptake was 
detected in Clcn5Y/- and Cftr∆F/∆F mPTC (panels D and G, respectively), with occasional 
colocalization of few gentamicin-positive vesicles with the lysosomal marker (panels F 
and I). Taken together, these data demonstrate that uptake of gentamicin and its 
progression along the endosomal-lysosomal pathway are affected by the functional loss 
of CFTR or ClC-5 in PT cells.  
 
Quantification of gentamicin endocytosis in mPTC from Clcn5 and Cftr mice 
To monitor the effect of CFTR or ClC-5 loss on gentamicin uptake, we incubated mPTC 
from ClCn5 and Cftr mice for 15 min with similar, non-toxic concentrations of 
E H F G 
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Alexa488-gentamicin or Alexa488-BSA, taken as a well-established ligand for megalin. 
The uptake of gentamiycin or albumin was then analyzed (i) under control conditions, (ii) 
in the presence of competitive inhibitors of megalin (excess of albumin) or cubilin 
(excess of transferrin), and (iii) in conditions of metabolic inhibition (Fig. 5). In control 
mPTC, the amount of accumulated gentamicin was similar to that of albumin (70 ± 4 vs. 
71 ± 2 ng/µg protein respectively). Competitive or metabolic inhibition could block 
gentamicin and albumin uptake by mPTC. As compared to wild-type mPTC, gentamycin 
and albumin uptake was reduced by ~75% in Clcn5Y/- mPTC and by ~20% in Cftr∆F/∆F 
mPTC. These results show that functional loss of ClC-5 or CFTR is reflected by a 
significant loss in the endocytic uptake of gentamicin (and albumin) by PT cells; this 
effect is much more pronounced in cells lacking ClC-5 than in those lacking CFTR.  
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DISCUSSION 
In this study, we analyzed the handling of AG by PT cells using in vivo and in 
vitro experiments performed on Cftr∆F/∆F and Clcn5Y/- mice. The increased gentamicin 
clearance we observed in both strains (+30% in Cftr∆F/∆F vs. +60% in Clcn5Y/- mice) was 
associated with a lower accumulation of the drug in the kidney. The reduction in 
gentamicin uptake was confirmed in mPTC obtained from Cftr∆F/∆F and Clcn5Y/- mice, 
with much fewer gentamicin-positive vesicles in the early endosomal and lysosomal 
compartments. Quantification of endocytosis in mPTC revealed a similar profile of 
uptake and inhibition for gentamycin and albumin. The endocytic uptake of albumin and 
gentamicin was shown to be significantly reduced in Cftr∆F/∆F and Clcn5Y/- mPTC, but 
this effect was much more pronounced in cells lacking ClC-5 than in those lacking 
CFTR. These results confirm the role of CFTR in PT cell endocytosis and demonstrate 
that the functional loss of CFTR, as that of ClC-5, is associated with a decreased efficacy 
of receptor-mediated uptake in PT cells, causing an enhanced AG clearance.  
 Among other factors, aggressive antibiotic treatment for lung infections has led to 
a dramatic increase in life expectancy for patients with CF over the last three decades 
[24]. Because of their efficacy against Pseudomonas aeruginosa, AG antibiotics are 
particularly useful to treat chronic lung infections in patients suffering from CF [2,21]. In 
the general population, up to 25% of treated patients will present AG-induced 
nephrotoxicity, despite accurate follow-up [14]. The renal toxicity of AG is clearly 
related to their uptake along the PT segments via receptor-mediated endocytosis [22], 
accumulation in endo-lysosomal vesicles, modification of the membrane phospholipid 
content, leakage in the cytosol, and subsequent toxicity for mitochondria and 
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endoplasmic reticulum, activating different pathways leading to cell death [14,23]. It is 
known for a long time that CF patients display an enhanced renal clearance for several 
drugs including AG [13,25,28]. Since protein binding is generally unchanged in CF 
patients and no significant differences in glomerular filtration rate (GFR) have been 
found in most studies [25,28], a possible role for defective endocytic uptake has been 
evoked. This hypothesis has first been substantiated by Jouret et al., who evidenced a 
defect in receptor-mediated endocytosis in CF mouse models and CF patients [11]. These 
studies revealed that CFTR, like ClC-5, is expressed in the endosomes of PT cells [7]. 
Mice knock-out for CFTR or harboring the F508del mutation presented with a mild but 
significant albuminuria and LMW-proteinuria, caused by a defective receptor-mediated 
endocytosis. Patients with CF showed a similar defect in LMW protein handling [11]. 
 To investigate the putative link between defective endocytosis and changes in 
gentamicin handling in CF, we compared the Cftr∆F/∆F mouse vs. the Clcn5Y/- mouse 
model of Dent's disease. The Cftr∆F/∆F mouse model bears the most common mutation in 
CF (F508del) [29], which results in misfolding and lack of maturation of CFTR that 
cannot reach the apical plasma membrane. Instead, the mutated protein does not escape 
the endoplasmic reticulum quality control and is degraded by the ubiquitin-proteasomal 
pathway [3]. However, the Cftr∆F/∆F tissues show a residual Cl- conductance, suggesting 
that the mutant F508del-CFTR is partially processed and reaches the plasma membrane 
in several tissues including the kidney [3,18]. This residual activity may explain, at least 
partially, the less severe PT phenotype in the Cftr∆F/∆F mouse as compared with the 
Clcn5Y/- mouse which displays a severe trafficking defect of megalin and cubilin resulting 
in a massive endocytic defect and generalized PT dysfunction [5,19,30]. Our data 
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confirm the quantitative difference in LMW proteinuria and extend it to the renal 
handling of gentamicin. The increased gentamicin clearance in both models could result 
from a decreased reabsorption as evidenced by a lower kidney gentamicin accumulation 
as assessed by immunostaining and quantitative AG analyses in kidney extracts.   
 Previous studies have identified receptor-mediated endocytosis through binding of 
megalin as the primary route of uptake for polybasic drugs such as AG [16,22]. Our in 
vivo studies show a mild (Cftr∆F/∆F) or dramatic (Clcn5Y/-) reduction in megalin staining in 
PT segments, which c uld explain the enhanced gentamicin clearance and the decreased 
renal accumulation. For a more comprehensive investigation of gentamicin handling by 
PT cells, we used primary cultures of mPTC which remain well differentiated and keep 
essential properties such as receptor-mediated endocytosis [27]. For instance, we recently 
showed that the endocytic defect of Clcn5Y/- mice was retained in primary cultured mPTC 
[20], and that these cells were responding to a transcriptional program of differentiation 
[26]. Using this system, we demonstrated that the lack of functional CFTR leads to a 
significant, ~20% decrease in gentamicin and albumin uptake, as compared with a major, 
~80% reduction in cells KO for ClC-5. The fact that similar proportions were obtained 
for gentamicin clearance and kidney accumulation highlights the correspondence 
between the distinct methodological approaches targeting the endocytic defect in vivo and 
in vitro. The sensitivity of gentamicin uptake to metabolic and competitive inhibition 
(with both excess of albumin and transferrin) identified the energy-demanding receptor-
mediated endocytosis pathway using the multiligand receptors megalin and cubilin as the 
primary uptake route for gentamicin in mPTC. Our investigation focusing on the 
trafficking of gentamicin by colocalization with endosomal and lysosomal markers 
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confirmed the AG processing in PT cells. In wild-type mPTC, gentamicin colocalized 
with EEA1 in the early endosomal pathway after 7 min incubation, whereas most of the 
gentamicin was localized in lysosomes after 45 min. The gentamicin uptake was reduced 
in Cftr∆F/∆F and Clcn5Y/- mPTC, but rare colocalization with endosomal and lysosomal 
markers could be observed. The fact that gentamicin is taken up by receptor-mediated 
endocytosis and routed to lysosomes opens possibilities to prevent drug accumulation in 
the PT and thus limiting nephrotoxicity. The search for strategies to prevent the binding 
of gentamicin to megalin has been initiated [14,15]. Finally, the enhanced excretion 
observed in the mouse models tested here may suggest that dosage adaptation and drug 
monitoring is particularly important when using AG in patients suffering from a defective 
endocytosis and LMW-proteinuria, including CF and Dent’s disease. 
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FIGURE LEGENDS 
Figure 1: Gentamicin uptake and megalin expression in Cftr and Clcn5 kidneys. 
Panel A. Immunostaining for gentamicin in Cftr and Clcn5 kidneys 24h post-injection of 
gentamicin (5mg/kg) showing segmental gentamicin staining in the proximal tubules 
(PT) of both wild-type Cftr+/+ and Clcn5Y/+ kidneys. In contrast, the staining  is abolished 
in the proximal tubules of Clcn5Y/- kidneys and is weakly detected in  Cftr∆F/∆F kidneys.  
Panel B. Immunostaining for megalin showing a strong expression at the apical region of 
the cells lining the proximal tubules in the wild-type Cftr+/+ and Clcn5Y/+ kidneys. In 
contrast, the  staining is almost undetectable in  Clcn5Y/- kidneys and is slightly decreased 
in Cftr∆F/∆F kidneys. Scale bar: 50µm (panel A), 100 µm (panel B). 
 
Figure 2: Gentamicin uptake in proximal tubule cells. 
 Primary cultures of proximal tubule cells (mPTC) obtained from Clcn5Y/+ (wild-type, 
panels A-D), Clcn5Y/- (panels E-H) and Cftr∆F/∆F (panels I-L) kidneys  exposed to 5 
mg/ml gentamicin ( 37°C for 7min or 45min). Staining with anti-gentamicin and labeling 
with Alexa488 IgG were analyzed by confocal microscopy. Nuclei  counterstained with 
DraQ5TM (red).  
In comparison with wild-type mPTC (A-B), Clcn5Y/- cells showed a drastically reduced  
early (7 min) uptake of gentamicin (E-F), while a milder reduction was observed in 
Cftr∆F/∆F mPTC (I-J). At 45 min, numerous large gentamicin-positive vesicles positive  
could be observed in wild-type mPTC (C-D). A smaller number of positive vesicles was 
detected in Clcn5Y/- (G-H) and Cftr∆F/∆F (K-L) mPTC. No difference in staining could be 
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observed between mPTC obtained from wild-type Clcn5Y/+ and Cftr+/+ kidneys and 
therefore a representative image of wild-type mPTC is shown. Scale bar: 10µm. 
 
Figure 3: Early localization of gentamicin in proximal tubule endosomes. 
 Primary cultures of Clcn5Y/+ (wild-type; panels A-C), Clcn5Y/- (panels D-F) and Cftr∆F/∆F 
(panels G-I) mPTC exposed to 5 mg/ml gentamicin (7 min at 37°C), fixed and stained 
with anti-gentamicin (Alexa488; A,D&G) and anti-EEA1 (Alexa568; B,E&H). Nuclei 
counterstained with DraQ5TM (blue). Gentamicin colocalizes with EEA1 in multiple 
vesicles in control mPTC, contrasting with a lower density of vesicles observed in the 
Clcn5Y/- and Cftr∆F/∆F cells (Merge panels, yellow spots). Scale bar: 10µm. 
 
Figure 4: Late localization of gentamicin in proximal tubule lysosomes. 
Primary cultures of Clcn5Y/+ (wild-type; panels A-C), Clcn5Y/- (panels D-F) and Cftr∆F/∆F 
(panels G-I) mPTC exposed to 1 mg/ml Alexa488-gentamicin (green; A,D&G) and 
LysoTracker Red (red; B,E&H) for 7 min at 37°C and followed up for 45min using live-
cell imaging. Gentamicin colocalizes with LysoTracker after 45min (yellow spots, merge 
panels), but a much lower density of positive vesicles observed in Clcn5Y/- and Cftr∆F/∆F 
cells. Scale bar: 5µm. 
 
Figure 5: Quantification of gentamicin uptake in mPTC. 
Primary cultures of wild-type (Wt) mPTC (open bars), Clcn5Y/- (striped bars) and 
Cftr∆F/∆F (dashed bars) mPTC exposed to 0.5 mg/ml Alexa488-gentamicin (white bars) or 
0.5mg/ml Alexa488-BSA (grey bars) for 15min at 37°C under control conditions or in 
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the presence of excessive amount of competitive inhibitors albumin (+Alb) or transferrin 
(+Tf) or after metabolic inhibition (MI). The uptake of albumin and gentamicin is 
decreased in a variable extent in the Clcn5Y/- vs. the Cftr∆F/∆F mPTC. The residual uptake 
after competitive inhibition with an excess of ligands or with metabolic inhibition is 
shown for comparison. 
Data are mean ± SEM of 6 experiments (n=6). Statistical differences are indicated with 
*p<0.001 and **p<0.01 vs. Wt mPTC. 
Page 24 of 32Pflugers Archiv-European Journal of Physiology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 25 
 
Table 1. Clinical and biochemical parameters in Cftr and Clcn5 mice 
 
 
Cftr+/+ Cftr∆/∆ ClCn5Y/+ Clcn5Y/- 
Body weight (g) 26.2 ± 1.3 25.2 ± 0.9 24.6 ± 0.4 29.1 ± 0.4b 
BUN (mg/dL) 25 ± 0.5 27 ± 3.3 27 ± 2.8 25 ± 1.7 
Plasma creatinine (mg/dL) 0.072 ± 0.02 0.076 ± 0.02 0.086 ± 0.02 0.08 ± 0.01 
Diuresis (µL/24h) 708 ± 87 704 ± 123 996 ± 176 2317 ± 447b 
Creatinine clearance 
(µL/min.g BW) 
37 ± 10 40 ± 7 17 ± 4 23 ± 3 
Urinary albumin (µg/g creat) 1893 ± 1385 10,869 ± 3513a 798 ± 761 58,608 ± 3041c 
Urinary CC16 (µg/g creat) 42 ± 23 132 ± 20a 1.7 ± 0.9 37,665 ± 10,877d 
 
ap<0.05 vs. Cftr+/+; bp<0.05 vs. Clcn5Y/+; cp<0.0001 vs. Clcn5Y/+; dp<0.01 vs. Clcn5Y/+ 
BUN, Blood urea nitrogen; there were 5 pairs of age- and gender-matched mice per 
genotype. 
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 Table 2. Gentamicin handling by Cftr and Clcn5 mice 
 
 
Cftr+/+ Cftr∆/∆ ClCn5Y/+ Clcn5Y/- 
Plasma gentamicin (µg/mL) 7.2 ± 0.5 7.9 ± 1.2 6.7 ± 0.6 8.8 ± 0.7 
Gentamicin clearance (mL/min) 5.2 ± 0.4 6.6 ± 0.7a 5.6 ± 0.5 9.3 ± 1.0b 
Kidney gentamicin (µg/mL) 0.89 ± 0.1 0.75 ± 0.1a 0.66 ± 0.1 0.1 ± 0.05c  
 
a p<0.05 vs. Cftr+/+; b p<0.01 vs. Clcn5Y/+; c p<0.0001 vs. Clcn5Y/+ 
There were 5 pairs of age- and gender-matched mice per genotype. 
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Figure 1 – Panel B
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